Update on the management of lupus nephritis: Let the treatment fit the patient

Nature Clinical Practice Rheumatology

Volumn 4, Issue 9, 2008, Pages 464-472

  Bertsias, George ^a   Boumpas, Dimitrios T ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; VITAMIN D;

ADJUVANT THERAPY; AMENORRHEA; ARTHRALGIA; BACTERIAL INFECTION; BLOOD DISEASE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSLIPIDEMIA; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEMBRANOUS LUPUS NEPHRITIS; NEPHRITIS; PATIENT CARE; PHOTODERMATOSIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; SURVIVAL TIME; URINARY TRACT INFECTION;

ALGORITHMS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CONTROLLED CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID;

EID: 51149105272     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0896     Document Type: Review

References (43)

1. Boumpas DT et al. (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741-745
2. Gourley MF et al. (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125: 549-557
3. Illei GG et al. (2001) Combination therapy with pulse cyclophosphamide plus pulse methylpredinisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135:248-257
4. Boumpas DT et al. (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119: 366-369
5. Houssiau FA et al. (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephntis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50: 3934-3940
6. Boumpas DT et al. (2005) Optimum therapeutic approaches for lupus nephritis: What therapy and for whom? Nat Clin Pract Rheumatol 1: 22-30
7. Grootscholten C et al. (2006) Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 70: 732-742
8. Grootscholten C et al. (2007) Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 56: 924-937
9. Mok CC et al. (2006) Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 119: E25-e33
10. Moore RA and Derry S (2006) Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 8: 1-10
11. Walsh M et al. (2007) Mycophenolate mofetil for induction therapy of lupus nephritis: A systematic review and meta-analysis. Clin J Am Soc Nephrol 5: 968-975
12. Zhu B et al. (2007) Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: A meta-analysis of randomized controlled trials. Nephrol Dial Transplant 22 1933-1942
13. A study of CellCept (mycophenolate mofetil) in management of patients with lupus nephritis. [http://clinicaltrials.gov/ct/show/NCT00121082] (accessed 17 July 2008)
14. Ginzler EM et al. (2007) Mycophenolate mofetil and intravenous cyclophosphamide in the Aspreva Lupus Management Study (ALMS): Efficacy by racial group. Presented at the. American College of Rheumatology Annual Meeting, 2007, Boston, MA [www.rheumatology.org]
15. Moroni G et al. (1996) "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 50: 2047-2053
16. Illei GG et al. (2002) Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 46:995-1002
17. Chan TM et al. (2005) Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 14:265-272
18. Moroni G et al. (2006) A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 1: 925-932
19. Chan TM et al. (2005) Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16: 1076-1084
20. Contreras G et al. (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971-980
21. Gottenberg JE et al. (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64: 913-920
22. Gunnarsson I et al. (2007) Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 56: 1263-1272
23. Looney RJ et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50: 2580-2589
24. Ng KP et al. (2007) B cell depletion therapy in systemic lupus erythematosus: Long-term follow-up and predictors of response. Ann Rheum Dis 66: 1259-1262
25. Sfikakis PP et al. (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum 52: 501-513
26. Smith KG et al. (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 54: 2970-2982
27. Tanaka Y et al. (2007) A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 17 191-197
28. Vigna-Perez M et al. (2006) Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res Ther 8: R83
29. Genentech Inc. website [http://www.gene.com/gene/news] (accessed 17 July 2008)
30. A study to evaluate the efficacy and safety of rituximab in patients with severe systemic lupus erythematosus (EXPLORER) [http://clinicaltrials.gov/ct/show/NCT00137969] (accessed 17 July 2008)
31. Study to evaluate the efficacy and safety of rituximab in subjects with ISN/RPS class III or IV lupus nephritis (LUNAR) [http://clinicaltrials.gov/ct/show/NCT00282347] (accessed 17 July 2008)
32. Ogawa H et al. (2007) Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Mod Rheumatol 17 92-97
33. Mok CC et al. (2005) Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study. Kidney Int 68: 813-817
34. Mok CC et al. (2004) Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: An open-label trial. Am J Kidney Dis 43:269-276
35. Moroni G et al. (1998) Treatment of membranous lupus nephritis. Am J Kidney Dis 31: 681-686
36. Spetie DN et al. (2004) Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 66: 2411-2415
37. Austin H et al. (2004) Lupus membranous nephropathy: Controlled trial of prednisone, pulse cyclophosphamide and cyclosporine A [abstract]. J Am Soc Nephrol 15: 54A
38. Kapitsinou PP et al. (2004) Lupus nephritis: Treatment with mycophenolate mofetil. Rheumatology (Oxford) 43:377-380
39. Karim MY et al. (2005) Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 44: 1317-1321
40. Borba EF et al. (2006) Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int 12 1078-1083
41. Tse KC et al. (2007) A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 16:46-51
42. Nikpour M et al. (2005) Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 31: 329-354
43. Bertsias GK et al. (2008) EULAR recommendations for the management of systemic lupus erytematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67:195-205